NCI-H838 Xenograft Model Service for NSCLC

The NCI-H838 xenograft model represents a distinctive in vivo platform for non-small cell lung cancer (NSCLC) research, particularly valuable for evaluating therapeutic candidates in a KRAS- and EGFR-wild-type genetic context. Alfa Cytology delivers fully customizable NCI-H838 xenograft services—from model establishment and tumor monitoring to endpoint analysis—enabling robust preclinical assessment of cytotoxic agents, apoptosis modulators, and immune-based interventions.

Overview of NCI-H838 Xenograft Model for NSCLC

The NCI-H838 cell line was originally isolated from a lung adenocarcinoma specimen obtained from a 67-year-old male patient and has since become a cornerstone of NSCLC preclinical research. Unlike many commonly employed lung cancer models that harbor activating mutations in KRAS or EGFR, NCI-H838 retains wild-type status at both loci, positioning it as an essential tool for investigating mutation-agnostic therapeutic strategies. The line exhibits classic epithelial morphology, expresses cytokeratin 7 and E-cadherin, and demonstrates reliable tumorigenicity when engrafted into immunodeficient murine hosts. Its moderate-to-rapid growth kinetics and reproducible histological architecture render it highly suitable for longitudinal efficacy studies, biomarker exploration, and combination regimen optimization.

Fig 1. A947 selectively degraded SMARCA2 across a lung cancer cell line panel including NCI-H838 and induced G1 cell-cycle arrest in SMARCA4-mutant models, supporting its in vivo efficacy in NCI-H838 xenografts. (Cantley, Jennifer, et al., 2022)

At the molecular level, NCI-H838 carries a mutant TP53 allele alongside a KEAP1 E444* nonsense mutation, features that confer sensitivity to DNA-damaging agents, cell-cycle checkpoint inhibitors, and compounds targeting the Nrf2 antioxidant pathway. Baseline PD-L1 expression is generally low yet inducible under inflammatory conditions, offering a window for immunogenicity-focused investigations. Collectively, these attributes make the NCI-H838 xenograft an indispensable asset for translational programs seeking to bridge in vitro findings with in vivo pharmacology in a genetically defined NSCLC setting.

Cell Line Information: NCI-H838

The NCI-H838 cell line (ATCC CRL-5844) was established from the primary lung tumor of a 67-year-old Caucasian male diagnosed with adenocarcinoma of the lung. The line grows as an adherent monolayer with epithelial morphology and has been authenticated via STR profiling. It is maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum at 37°C under 5% CO₂. The table below summarizes its key biological and molecular characteristics.

Our Services

Alfa Cytology specializes in building and executing NCI-H838 xenograft studies tailored to the unique demands of each preclinical program. Our team manages every phase—from cell-line authentication and health-status verification to tumor implantation, randomized grouping, dosing administration, and comprehensive endpoint analysis—ensuring data integrity and regulatory compliance throughout. Whether your objective is to benchmark a novel compound against standard-of-care platinum agents, evaluate combination schedules with immune-checkpoint modulators, or profile pharmacodynamic biomarkers, we provide the technical infrastructure and scientific oversight to drive your NSCLC pipeline forward with confidence.

Workflow of NCI-H838 Xenograft Model Construction

Establishing a reliable NCI-H838 xenograft model requires meticulous attention to cell quality, animal welfare, and standardized operational procedures. At Alfa Cytology, each study adheres to IACUC-approved protocols and follows a structured workflow designed to maximize tumor take rates, minimize inter-animal variability, and generate pharmacologically meaningful datasets. The process unfolds across the following stages:

1. Cell Preparation and Quality Verification: NCI-H838 cells are expanded under standardized culture conditions and subjected to mycoplasma testing, STR authentication, and viability assessment prior to harvest. Only cultures exceeding 95% viability are qualified for implantation.
2. Recipient Mouse Selection and Acclimation: Immunodeficient strains (e.g., BALB/c nude or NOD/SCID) are screened for health status and acclimated for a minimum of five days. Body weight and baseline clinical observations are recorded to ensure uniform cohort health at study initiation.
3. Tumor Cell Inoculation: A single-cell suspension (typically 1 × 10⁶ to 5 × 10⁶ cells in 100–200 µL of serum-free medium, optionally mixed 1:1 with Matrigel™) is injected subcutaneously into the flank of each mouse using aseptic technique.
4. Tumor Monitoring and Randomization: Tumor development is monitored by palpation and caliper measurement every 2–3 days. Once tumors reach a predetermined volume (commonly 100–150 mm³), animals are randomized into treatment and control groups using a stratified randomization algorithm based on tumor size and body weight.
5. Dosing Administration and Clinical Surveillance: Test articles are administered according to the study-specific protocol (route, frequency, and duration defined by the sponsor). Throughout the dosing period, mice are evaluated daily for body weight, clinical signs, and any treatment-related adverse events, with humane endpoints strictly enforced.
6. Endpoint Analysis and Data Compilation: At study termination, tumors are excised, weighed, and photographed. A subset may be preserved for histopathology (H&E, IHC), biomarker analysis (Western blot, qPCR, flow cytometry), or pharmacokinetic/pharmacodynamic correlation. All data are compiled into a comprehensive study report with statistical analysis.

Fig 2. NCI-H838 xenograft model construction workflow.

Case Study-NCI-H838 Xenograft Model Development

In a recent preclinical engagement, Alfa Cytology established subcutaneous NCI-H838 xenografts in BALB/c nude mice to evaluate the antitumor activity of a novel MAT2A inhibitor in an MTAP-deficient NSCLC background. Following a 10-day engraftment period, tumors achieved measurable volumes and animals were randomized into vehicle-control and treatment cohorts receiving once-daily oral dosing. The study tracked tumor growth inhibition over a three-week treatment window, with interim caliper measurements revealing dose-dependent suppression of tumor expansion. Endpoint analysis demonstrated significant reductions in tumor mass across treated groups relative to controls, accompanied by corresponding decreases in intratumoral SAM and symmetric dimethylarginine (sDMA) levels—consistent with on-target MAT2A engagement. Pharmacokinetic sampling confirmed adequate systemic exposure, and histopathological examination of major organs showed no unexpected toxicological findings. These results illustrate the utility of the NCI-H838 platform for validating mechanism-driven hypotheses and prioritizing lead compounds with favorable efficacy–safety profiles prior to IND-enabling studies.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your NCI-H838 xenograft program means gaining access to a scientifically rigorous, operationally flexible CRO capable of accelerating your NSCLC drug-discovery timeline. Our distinguishing strengths include:

• Genetically characterized cell banks with verified STR profiles and documented mycoplasma-negative status, ensuring reproducible tumor biology across studies.
• Flexible study designs accommodating single-agent, combination, dose-escalation, and biomarker-driven endpoints tailored to your translational objectives.
• Real-time tumor monitoring via digital caliper measurements and optional non-invasive imaging modalities (bioluminescence, MRI) for longitudinal pharmacodynamic readouts.
• Integrated histopathology and molecular analysis capabilities, including IHC, Western blot, qPCR, and flow cytometry, all performed under one roof.
• Strict adherence to IACUC guidelines, GLP-compliant data management, and transparent communication through dedicated project scientists.
• Rapid study initiation timelines with established NCI-H838 colonies, enabling enrollment and first dosing within weeks of contract execution.

Contact Us

If you are seeking a reliable preclinical partner to advance your NSCLC therapeutic pipeline, we invite you to reach out to Alfa Cytology today. Our scientific team is ready to discuss your specific requirements, propose a customized study protocol, and provide a detailed quotation aligned with your budget and timeline. Whether you need a standard efficacy study or a complex combination regimen with integrated biomarker analysis, we are committed to delivering high-quality data that informs your next critical decision. Contact us now to initiate your NCI-H838 xenograft program and move one step closer to clinical translation.

For research use only. Not intended for any clinical use.